Viking Therapeutics Inc (VKTX)

[IOUBLOKE1]

after hours 5 million wxchanged in blocks

[tootalljones]

jim
50 minutes ago
Bullish
Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion
Waiting for VTKX to be acquired

[tootalljones]

Jason
41 minutes ago
Novartis' acquisition of Chinook proves that big co's sitting on piles of cash are looking. It's only a matter of time. Short at your own risk.

[tootalljones]

This Red-Hot Growth Stock Has Soared 885% in Just 12 Months
By David Jagielski – Jun 8, 2023 at 10:07AM
KEY POINTS
Viking Therapeutics is a biotech with multiple potential blockbuster drugs in its portfolio.
Encouraging trial results have made investors bullish about the stock's prospects.
Motley Fool Issues Rare “All In” Buy Alert
_______________________
the reference is to Viking Therapeutics
https://www.fool.com/investing/2023/06/08/this-red-hot-growth-stock-has-soared-885-in-just/

[tootalljones]

see ya at 50 bucks by October 15th, as the market grudgingly starts to provide a rational value assessment. The big fear this year is a buyout. No doubt it is being watched now.

[tootalljones]

barebones article saying Viking is hot among all its analysts. What is interesting is that they feature the obesity candidate ahead of the NASH candidte. The Obesity/diabetes candidate looks to drop weight by 8 percent,= massive effectiveness. This would impact the global diabetes and cardio and obesity population enormously. There have been sugar/caffeine candidates loved by the phonies on Wall Street that heavily endorsed such retro formulations with claimed effectiveness of 2 percent...garnering market caps of 5 BILLION DOLLAR MARKET CAPS....before eventually the market sniffing these drugs (which were in phase 2 testing) to be essentially worthless. How the heck can Viking candidate not on its own justify a 5 billion dollar market cap? People will say, yea yea it is young blah blah blah....
and the lead NASH applicant is clearly safe and is the most effective drug candidate on the planet for this liver condition, a domestic market of 16 billion dollar per analysts..........justifying a 500 share price.

[tootalljones]

inside the recent May 16, 2023 press release that the drug met all endpoints, is this little incredible cardiovascular nugget worth its weight in gold. It looks also like a tremendous cardio drug. How big is that market again?:
"These results demonstrate VK2809's impressive potency at reducing liver fat, which we believe represent the largest reductions reported for an oral agent at this stage of development," stated Brian Lian, Ph.D., chief executive officer of Viking. "The high response rates observed in this study suggest improved probabilities of histologic benefit, as has been demonstrated in published clinical studies. In addition, VK2809's consistent effect at reducing plasma lipids provides further support for its role in improving the metabolic profile of patients suffering from NASH. These results align well with those reported from our prior 12-week NAFLD study, but in a more severe population and at lower doses. VK2809's excellent safety and tolerability further establish its best-in-class profile, with rates of drug-related adverse events, including GI-related events such as nausea and diarrhea, that are similar to placebo. We believe these data suggest important benefits for patients with NASH, and look forward to reporting the 52-week biopsy data from this study in the first half of next year."
Reduction in Plasma Lipids
Consistent with prior studies, patients receiving VK2809 demonstrated statistically significant placebo-adjusted reductions in LDL-C ranging from 11% to 20%, as well as statistically significant reductions in triglycerides and atherogenic proteins such as apolipoprotein B (ApoB), lipoprotein (a) [Lp(a)], and apolipoprotein C-III (ApoC-III). Reductions in these plasma lipids improve a patient's overall cardiometabolic profile and may reduce the risk of cardiovascular-related events.
Safety and Tolerability
VK2809 demonstrated encouraging safety and tolerability in this study. The majority (94%) of treatment related adverse events among patients receiving VK2809 were reported as mild or moderate. Discontinuations due to adverse events were low

[tootalljones]

The May 15, 2023 conf call. Company is sitting on two major blockbusters. The NASH application alone (There are no approved drugs and Viking has the most effective, safe candidate which this conf call is about), is projected to be a 16 billion dollar per year application by the year 2030. The Obesity candidate obviously has an even more astronomical annual market, because it addresses the global obesity pandemic. In fact the press release for the NASH drug also has many valuable nuggets which address the massive cardio market. https://app.webinar.net/Qa5vGzKAd4z/on-demand

[randychub]

I picked up 6k shares today at 22.

Another use for GLP-1. My daughter has Down syndrome, OCD and Autism. About 3 years ago she was having meltdowns every day. I literally had to hold her down to keep her from hurting herself.

Eventually ended up putting her in respidone and upon raising dose every few months. That caused weight gain and in general she was just never the same as before the meltdowns started. I started her on semaglutide and B12 for the weight gain. With in 2 days she was back to smiling happy person that I had not seen in years.

I googled and found a few other cases that have had same results as my daughter.

Recent advances show that the gut-brain hormone ghrelin modulates aggressive behaviors. As the gut-brain hormone glucagon-like peptide-1 (GLP-1) reduces food intake and sexual behaviors its potential role in aggressive behaviors is likely. Therefore, we investigated a tentative link between GLP-1 and aggressive behaviors by combining preclinical and human genetic-association studies. Bla bla bla. The influence of acute or repeated injections of a GLP-1 receptor (GLP-1R) agonist. Overall, GLP-1 signaling suppresses acquisition of aggressive behaviors via central neurotransmission and additional studies exploring this link are warranted.

[Glider549]

YES!!!
Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in Liver Fat from Baseline to Week 12 in Patients Receiving VK2809 as Compared to Placebo
Up to 52% Mean Liver Fat Reduction Observed in VK2809-Treated Patients
Up to 85% of Patients Experienced at Least a 30% Relative Reduction in Liver Fat
Statistically Significant Reductions in LDL-C, Triglycerides, and Atherogenic Lipoproteins Observed
Adverse Events, Including GI-Related AEs, Similar Among VK2809-Treated Patients vs. Placebo

[budgetthis]

The Analysts love us……whether that’s a good thing is yet to be determined…..lol.

Gimme $25 by June, please !

$$ VKTX $$

[roadkilll]

Why is management pushing a drug that is 10 years from market and will be a me too drug that needs hundreds of millions to get approval and will face generics if ever approved?
VK2809 should be the focus and seeing management pumping early phase I me too drugs is shady.

[IOUBLOKE1]

question is will there be an offering as they exchanged shares for cash??? 25 or 15 what us the next move

[budgetthis]

Give me $25 in May……

Hope springs eternal…….in spring…..lol.

$$ VKTX $$

[roadkilll]

Selling here.
When the price runs this hard on news about a drug where they are in the planning stage for a phase I trial on a me too drug? GLTA,

[budgetthis]

Great call……!

Seems the market is taking the news of the offering pretty well at this time.

$$ VKTX $$

[The Canes]

I'd expect a secondary is right around the corner. It'd be a great time to buy a few more shares on a short term pull back. The pull back may only last a few hours!

[budgetthis]

Let’s just hit $20 in the next few days…..

We rock……Analysts love us……what’s not to love……lol.

$$ VKTX $$

[CanuckCa$h]

...and now $16! :)

[The Canes]

Your prediction came true we hit $15 today. When this was trading for under $3 bucks last September I thought it was a zombie loser. I took 25% of my holdings off the table today. Now I'll let it ride!

[roadkilll]

The stock keeps pushing green no matter how red the market gets. I'm guessing the unknown is is known to some and it's good.

[budgetthis]

Excellent day, Budget…….

Exactly, Budget……let’s hit $15 this month.

$$ VKTX $$

[Alan Brown]

Good or bad?

[roadkilll]

You can have a double blinded trial but the results can become obvious. Looks like that is happening here.

[roadkilll]

Phase II data coming in second quarter
Good data and I'm guessing buyout will soon follow. If 1mg and 2mg dose are potent enough to target NAFLD the buyout price is gonna surprise everyone.
Madrigal data will also move Viking and if/when FDA grants Accelerated Approval it is going to be a big validation for this class of drug.

[TheFinalCD]

`10.10 everybody win$

[roadkilll]

$9.99 this am.
The shorts really need to find something to focus bashing on today. Otherwise I think we continue trend higher into Madrigal getting Accelerated Approval, that is a big derisk catalyst, or the readout that comes with the data release from Viking trial.How soon?
Primary Outcome Measures :
Liver Fat [ Time Frame: 12 weeks ]
Relative change in liver fat content (assessed by MRI-PDFF) from baseline to Week 12 in subjects treated with VK2809 compared to the change in subjects treated with placebo.

Madrigal Accelerated Approval progress should be updated in their CC later this month.
April looks like a very big month if the top line data looks as good as I expect

[budgetthis]

Come on, VKTX !!

[TechandBio]

Added a few today New 52 week highs then double digits.


$VKTX

[TheFinalCD]

$VKTX looks like 9's coming

[TechandBio]

Added this am 8.23-8.25

$VKTX

[TechandBio]

Added some today at 8.05-8.10

$VKTX

[TechandBio]

I'm going to keep my entire position and double my stash next week.
Made a fortune in the space and I think gains will continue to increase next 12-24 months.

$VKTX

[TechandBio]

No one loved it under $3.00
always early!

$VKTX

[TechandBio]

Selling half my shares at $12.50 then let the other half run the houses money.
Adding end of Feb options.

$VKTX

[L0tsaluck2000]

what are you valuing the IP at?

[BottomBounce]

$VKTX Book Value only $1.97 has $1.64M DEBT

[roadkilll]

The Analyst
Maxim Group analyst Jason McCarthy maintained his Buy rating on Viking and raised the price target from $8 to $14.

The Thesis
Madrigal's M1-3196, a thyroid hormone receptor beta agonist, belongs to the same class of drug as Viking's 2809, McCarthy said in a Thursday note.

The data for MI-3196 suggest this class of drugs could successfully treat NASH, the analyst said.

Liver fat reduction is predictive of NASH and NAS improvements, and liver fat reduction achieved at 12 weeks was maintained at 36 weeks, McCarthy said, detailing takeaways from Madrigal's data. Additionally, NASH resolution did not worsen fibrosis, the analyst said.

Phase 2 data for VK2809 in treating NAFLD/hypercholesterolemia is due in the second half of the year, McCarthy said.

Comparing MI-3196 and VK2809, the analyst said the latter is more potent and targeted than the former, and the latter's dosing of 10mg/day is significantly lower than the former's 80mg/day.

"Nonetheless, the bottom line, in our view, is [that] success for Madrigal is a positive for Viking and VK2809."

[tootalljones]

100 percent true. the medical industry has lost its morals this century in the pursuit of profits.

[XenaLives]

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

  
  Settlement Date/Short Interest/Percent Change/  
  Average Daily Share Volume/Days to Cover  
  
  05/13/2022	4,489,190	16.44	  874,561	5.13 
  04/29/2022	3,855,387	 4.25	  963,159	4.00 
  04/14/2022	3,698,369	 3.82	  784,592	4.71  
  03/31/2022	3,562,356	(20.18)	1,276,819	2.79  
  03/15/2022	4,463,076	  2.49	  780,466	5.72  
  02/28/2022	4,354,553	  5.05	1,141,138	3.82  
  02/15/2022	4,145,163	(4.26)	1,128,714	3.67  
  01/31/2022	4,329,470	18.97	1,517,532	2.85  
  01/14/2022	3,639,034	(0.65)	1,122,353	3.24  
  12/31/2021	3,662,710	(11.90)	  752,924	4.86  
  12/15/2021	4,157,631	(15.83)	1,013,911	4.10  
  11/30/2021	4,939,519	 3.29	  626,906	7.88  
  11/15/2021	4,782,042	(3.95)	  682,478	7.01  
  10/29/2021	4,978,819	 4.72	  563,617	8.83  
  10/15/2021	4,754,337	(6.31)	  463,906      10.25  
  09/30/2021	5,074,576	(13.43)	  622,927	8.15  
  09/15/2021	5,861,734	(7.98)	  702,044	8.35  
  08/31/2021	6,369,946	(13.65)	  700,582	9.09  
  08/13/2021	7,377,030	(9.09)	  577,268      12.78  
  07/30/2021	8,114,425	 2.81	  583,170      13.91  
  07/15/2021	7,892,883	(3.03)	  678,849      11.63  
  06/30/2021	8,139,602	(17.77)	1,344,492	6.05  
  06/15/2021	9,898,014	(2.47)	  995,026	9.95  
  05/28/2021	10,148,533	(5.75)	  982,073      10.33  
  05/14/2021	10,768,141	 1.68	  830,745      12.96  
  04/30/2021	10,590,475	(4.60)	  774,264      13.68  
  04/15/2021	11,101,318	10.45	  743,411      14.93

[XenaLives]

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

 
 Settlement Date/Short Interest/Percent Change/ 
 Average Daily Share Volume/Days to Cover 
  
 03/31/2022	3,562,356	(20.18)	1,276,819	2.79 
 03/15/2022	4,463,076	  2.49	  780,466	5.72 
 02/28/2022	4,354,553	  5.05	1,141,138	3.82 
 02/15/2022	4,145,163	(4.26)	1,128,714	3.67 
 01/31/2022	4,329,470	18.97	1,517,532	2.85 
 01/14/2022	3,639,034	(0.65)	1,122,353	3.24 
 12/31/2021	3,662,710	(11.90)	  752,924	4.86 
 12/15/2021	4,157,631	(15.83)	1,013,911	4.10 
 11/30/2021	4,939,519	 3.29	  626,906	7.88 
 11/15/2021	4,782,042	(3.95)	  682,478	7.01 
 10/29/2021	4,978,819	 4.72	  563,617	8.83 
 10/15/2021	4,754,337	(6.31)	  463,906      10.25 
 09/30/2021	5,074,576	(13.43)	  622,927	8.15 
 09/15/2021	5,861,734	(7.98)	  702,044	8.35 
 08/31/2021	6,369,946	(13.65)	  700,582	9.09 
 08/13/2021	7,377,030	(9.09)	  577,268      12.78 
 07/30/2021	8,114,425	 2.81	  583,170      13.91 
 07/15/2021	7,892,883	(3.03)	  678,849      11.63 
 06/30/2021	8,139,602	(17.77)	1,344,492	6.05 
 06/15/2021	9,898,014	(2.47)	  995,026	9.95 
 05/28/2021	10,148,533	(5.75)	  982,073      10.33 
 05/14/2021	10,768,141	 1.68	  830,745      12.96 
 04/30/2021	10,590,475	(4.60)	  774,264      13.68 
 04/15/2021	11,101,318	10.45	  743,411      14.93

[XenaLives]

Other Pipeline Programs


Type 2 Diabetes
VK0612 is a potent, orally available, inhibitor of fructose-1,6-bisphosphatase. VK0612 has successfully completed six Phase 1 trials and a Phase 2a proof of concept study. Five of the Phase 1 trials demonstrated the safety, tolerability, and pharmacokinetic profile of VK0612 in healthy volunteers. The sixth Phase 1 trial was a Phase 1b study in patients with poorly-controlled type 2 diabetes. The Phase 1b and 2a studies demonstrated the safety and clinical proof-of-concept for inhibition of fructose-1,6-bisphosphatase as a potential therapy for type 2 diabetes.

Phase 2a Proof-of-Concept Summary
The Phase 2a proof-of-concept trial was conducted in patients with moderate to severe type 2 diabetes. In this trial, patients received either placebo or VK0612 (10, 50, 100 or 200 mg capsule) once-daily for 28 days. At the highest dose, a statistically significant and clinically meaningful reduction in fasting plasma glucose (FPG) from baseline was achieved on Day 28 relative to placebo (mean placebo-adjusted change of -28.9 mg/dL). In the subgroup of patients with baseline FPG ≥ 180 mg/dL treated with 200 mg, the decrease in FPG was even more substantial (-49.7 mg/dL, placebo-adjusted). The overall incidence of treatment-emergent adverse events during the trial was low, including GI events. Moreover, mean fasting plasma lactate levels remained within normal limits in all groups, and no sustained lacticemia (lactate >4.5 mM on two consecutive visits) was observed.

(more at link)

DGAT-1 Inhibitor Program
DiacylGlycerol Acyl Transferase-1 (DGAT-1) is a key enzyme involved in the formation of triglycerides and is highly expressed in human fat metabolism sites such as intestine, liver, and adipose. Dietary triglycerides cannot be absorbed directly in the gastrointestinal, or GI, tract and are broken down into free fatty acids and monoglycerol in the intestine by pancreatic lipase. Once absorbed, the free fatty acids and glycerol are reassembled into triglycerides at the site of absorption, called an enterocyte, and packaged into chylomicron particles to be transported in the lymphatic system to be used throughout the body. DGAT-1 is one of two enzymes that catalyze the steps of triglyceride biosynthesis from mono- or diacylglycerol and fatty acids, and is mainly distributed in the intestine, liver and adipose tissue.

(more at link)


EPOR Agonist Program
Erythropoietin (EPO) acts on its receptor to stimulate the differentiation of bone marrow hematopoietic cells to form red blood cells. Various recombinant human EPO derivatives are marketed as erythropoiesis-stimulating agents (ESAs) for the treatment of anemia due to renal failure or cancer chemotherapy (e.g., Aranesp™, Epogen™, Eprex™, and Procrit™).

Epogen Receptor Activation Stimulates Multiple Signaling Pathway
EPOR

Activation of downstream signaling pathways results in proliferation, survival (anti-apoptosis) and differentiation of thyroid progenitor cells into red blood cells

We have developed a series of orally-available, small molecule agonists of the EPO receptor that may provide additional benefit in the treatment of anemia with improved safety, tolerability, and patient acceptance due to the convenience of oral administration and the lack of excessive erythropoietic stimulation. Anemia results from a decrease in red blood cells and is typically experienced by patients with renal complications, cancer patients and HIV/AIDS patients. These patients currently receive recombinant human EPO and other erythropoiesis-stimulating agents, or ESAs.

(more at link)

https://www.vikingtherapeutics.com/pipeline/other-pipeline-programs/

[XenaLives]

VK5211 Selective Androgen Receptor Modulator
Hip Fracture
Pills

Overview & Profile
Our lead clinical program is VK5211, a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 belongs to a family of novel non-steroidal SARM compounds based on tissue-specific gene expression and other functional, cell-based technologies. We expect VK5211 to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration.


Goals of SARM Therapy
-Improve Lean Body Mass (LBM)
-Improve Muscle Strength
-Improve Bone Strength
-Improve Physical Performance
-Enhance Quality of Life (QOL)

https://www.vikingtherapeutics.com/pipeline/musculoskeletal-program/

[XenaLives]

X-Linked Adrenoleukodystrophy

X-ALD is a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is the most frequent inherited peroxisomal disorder, affecting approximately 1 in 17,000 newborns.1 The disease is caused by mutations in a peroxisomal transporter of very long chain fatty acids, or VLCFA, known as the adenosine triphosphate binding cassette transporter D1, or ABCD1. As a result of mutations, transporter function is impaired and patients are unable to efficiently metabolize VLCFA. The TRß receptor is known to regulate expression of an alternative VLCFA transporter, known as ABCD2.

VK0214 is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for the beta receptor subtype. Data from an in vivo proof-of-concept study of VK0214 in X-ALD were presented at the 87th Annual Meeting of the American Thyroid Association, in Victoria, British Columbia. The results of this study demonstrated that long-term (25-week) treatment with VK0214 produced statistically significant reductions in plasma and tissue levels of very long chain fatty acids (VLCFAs) compared to vehicle-treated controls. VLCFA levels in central nervous system (CNS) tissues were also significantly reduced, suggesting a potential direct benefit in both brain and spinal cord. Treatment with VK0214 was also shown to stimulate significant increases in ABCD2 transporter expression in CNS tissue, providing further evidence of its effect beyond plasma exposures. These study results were consistent with the proposed mechanism of thyroid receptor beta (TRb)-mediated reductions in VLCFA levels, as ABCD2 is regulated by TRb and known to play a role in VLCFA metabolism. The successful outcome of this work serves to provide support for the role of selective TRb activation as a potential therapeutic approach to the disease. The company plans to file an IND for VK0214 in X-ALD by mid-year 2020.

https://www.vikingtherapeutics.com/pipeline/rare-disease-programs/

[XenaLives]

VK2809
Selective Thyroid Receptor-ß Agonist
Liver Disorders


Overview & Profile
We are developing a unique series of selective thyroid hormone receptor beta (TRß) agonists for metabolic disorders. Our lead candidate, VK2809, is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for liver tissue, as well as the beta receptor subtype, suggesting promise for the treatment of metabolic disorders, including non-alcoholic steatohepatitis (NASH). The liver-targeting properties of our TRß agonists are designed to reduce or eliminate the deleterious effects of extra-hepatic thyroid receptor activation. In particular, high tissue and TRß selectivity may lead to reduced activity at the TRa receptor, which can be associated with increased respiration and cardiac tissue hypertrophy.

Thyroid hormones are known to reduce body mass, affect growth, modulate lipid metabolism and impact the functions of multiple organs in humans. Their physiologic activity is derived from binding to hormonal receptors located in the nuclei of cells (nuclear hormone receptors). Characteristics of thyroid hormone activity that are of importance to drug development include the ability to reduce atherogenic lipids associated with cardiovascular disease and induce an increase in metabolism, resulting in weight loss. Patients with abnormally high or low thyroid hormone levels demonstrate clinical profiles consistent with these characteristics. Numerous animal models have provided further support of these physiologic effects.

thyroid-receptor-overview
Graphic: Harrison’s Principles of Internal Medicine, 17th Edition, Chapter 335, Fig 335-4, copyright McGraw-Hill, 2008.
Thyroid Receptor Subtypes

https://www.vikingtherapeutics.com/pipeline/metabolic-disease-program/

[XenaLives]

Pipeline:

[XenaLives]

At some point medical practice needs to stop treating symptoms and start treating the cause of the disease. Long term conditions and diseases of aging are usually due to systemic dysfunction on the mitochondrial level. Treating symptoms just leads to additional dysfunction known as "side effects".

These commercials drive me crazy. Physicians frequently over prescribe and improperly prescribe psychiatric meds, see this link:tarditive dyskenesia causes

https://www.youtube.com/watch?v=5JAE28ts_3M

https://www.youtube.com/watch?v=gLB5XWAQzBE

The answer is to tread dysregulation at the molecular level without side effects:

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.
Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).

Viking’s other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator. In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared with patients who received placebo. Other programs also include two earlier-stage programs targeting metabolic diseases and anemia. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

https://www.vikingtherapeutics.com/about/

[roadkilll]

And doubled down today. Hope the buyback folks did the same.

[roadkilll]

Time to buy back shares. The big data releases coming over the next few weeks are likely to verify the impressive date discussed int the liver conference.

Biomarkers continue to correlate with disease state and with treatment response. Expecting 30% of responders to completely reverse NASH. Safety of beta/liver focused thyroid drug is looking safer than the thyroid treatments ten of millions in US take daily. Thyroid supplements now have a 100 year safety record.

[roadkilll]

Look at Madrigal's move from $74 to $98 in the 5 days since revealing the phase III data that will be released in an oral presentation at a major liver conference on Nov 12.

Oral presentation means significant news. Companies don't apply for an oral presentation at a major conference unless the news is positive.

Viking will move with Madrigal news as it always has done.